arrow
S

Stephen J. Kerr

hiv-nat thai red cross aids and infectious diseases research centre
H指数:47
被引数:8,916

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment Outcomes of Total Versus Superficial Parotidectomy With Postoperative Radiotherapy for High-Grade Parotid Carcinoma Confined to the Superficial Lobe: A Propensity Score-Adjusted Analysis

高分级局限于浅叶的腮腺癌行全腮腺切除术与浅叶切除术联合术后放疗的治疗效果比较:一项倾向性评分调整分析

2026-09-010
PRE
Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者中显著肝纤维化的风险:一项前瞻性队列研究

2026-03-010
PRE
The Dynamics of Human Cytomegalovirus Markers in Tuberculosis Disease Among People With Human Immunodeficiency Virus on Long-term Antiretroviral Therapy: A Nested Case-Control Study

人类巨细胞病毒标志物在长期接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者结核病中的动态变化:一项巢式病例对照研究

2026-01-140
OA
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients

利福喷丁每月一次用于潜伏性结核病治疗的药代动力学和耐受性研究:在血液透析患者中的研究

2025-12-010
PRE
NAT2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic-Pharmacokinetic Cohort Study

NAT2多态性与抗结核药物诱导的肝毒性:基于泰国人类免疫缺陷病毒感染者药效遗传-药代动力学队列研究的见解

2025-10-010
PRE
One-year survival rate of unresectable pancreatic cancer size smaller than 4 cm treated with or without EUS-RFA

不可切除性胰腺癌患者,肿瘤直径小于4 cm,接受或不接受EUS-RFA治疗后的1年生存率

2025-07-170
PRE
No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study

泰国变性女性中口服TAF为基础的PrEP与雌性化激素疗法之间无显著药物相互作用:iFACT-3研究

2025-05-190
OA
Cause of death in people living with HIV who initiated antiretroviral therapy after enrolling to the Thai National AIDS Program from 2008 to 2021

2008年至2021年间,泰国国家艾滋病项目登记后开始抗逆转录病毒治疗并伴有HIV感染者的死亡原因

2025-05-010
PRE
Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study
2024-01-292
OAAI